Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (183)	12/1/1998 5:16:00 PM
From: Mike K	Read Replies (1) \| Respond to of 804

Peter and Thread! Some clarification regarding Multiple Myeloma. Current incidence rate is approximately 3-4 per 100,000 in the US, Canada and Europe. Asian countries have a lower rate of approx. 2 per 100,000. Although the median survival is around 2 years MANY patients today have had the disease for many years. I know several who have had the illness for over 10 years with very little treatment. The point is this is usually a slow moving cancer of the bone marrow. More specifically, it is uncontrolled growth of plasma cells. The transplants referred to in the Arkansas studies are Autologous Peripheral Blood Stem Cell Transplants. The patients were their own donors. The patients in the Arkansas study have advanced disease. Of particular interest to researchers in several centers are the effects of Thalidomide on newly diagnosed early stage patients. Many hem/oncs are excited about this drug including my own. Cheers, Mike dx Smoldering IgD Myeloma, 4/97 Part of phase 1 Gene Therapy study long Celg & Sugn

To: Biomaven who wrote (183)	12/1/1998 9:43:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 804

Peter: <<If I'm right, the stock is very cheap at these levels, although CELG will probably need one more trip to the financing well. >> I agree that based solely on thalidomide stock is cheap and that another financing is very possible. However, as you know last finance was ~9 MM debenture for ~800K common. This is only for two Q! So, my question is why finance for only two Q when VC was offering bigger support (according to rumor). I have four scenario: 1. Company is anticipating stock price rise and additional financing will be less dilutive to current SH. 2. Company is planing for another secondary because of the growing interest. 3. Company anticipate significant thalidomide revenue so burn rate will decrease significantly or maybe cover company expense, positive zero! 4. Company is negotiating partner(s) for US (+)-Ritalin right, SelCIDS, thalidomide analogue and expect significant cash infusion from licensers. Normally, I am not crazy enough to exclude 1. and 2. scenario. Still, based on current development and trend in life science scenario 3.& 4. are not far away from reality, imo. Miljenko